MarketLens
Sign Up

Why Did Raymond James Downgrade BridgeBio Pharma

4 months ago
SHARE THIS ON:

Why Did Raymond James Downgrade BridgeBio Pharma

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 months ago

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

BridgeBio Pharma launched a secondary offering of 5M shares by KKR Genetic Disorder L.P., with no proceeds to the company. The sale could pressure shares near-term due to added supply.
Stock News•3 months ago

BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment

BridgeBio Oncology Therapeutics fell >30% since prior coverage, but remains a Buy with BB-8520 showing 65% ORR and 100% DCR in KRAS G12C NSCLC. Mature data readouts due 2H26 could be key catalysts.
Stock News•3 months ago

BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?

BridgeBio Pharma (BBIO) rose 15.1% on above-average volume, but recent earnings estimate revisions suggest limited further upside.

Breaking News

View All →

Top Headlines

View More →
Stock News•28 minutes ago

Microsoft AI chief says the company beat OpenAI at its own game, using a quarter of the computing power

Stock News•30 minutes ago

Google warns suspected China-linked hackers could exploit BeyondTrust flaw

Stock News•1 hour ago

Tesla's Energy Boss Leaves the Company

Stock News•2 hours ago

Why This Market Washout Will Spark a Year-End Rally

Stock News•2 hours ago

Here Are the 3 Magnificent Seven Stocks I'd Buy Today